Historique
Article de Périodique
Management of pregabalin use disorder: A case series (2022)
Auteur(s) :
L. LANGLUME ;
C. EIDEN ;
S. ROY ;
F. TARUFFI ;
J. GAMBIER ;
H. DONNADIEU-RIGOLE ;
H. PEYRIÈRE
Article en page(s) :
386-391
Sous-type de document :
Etude de cas / Case report
Domaine :
Autres substances / Other substances
Langue(s) :
Anglais
Discipline :
PRO (Produits, mode d'action, méthode de dépistage / Substances, action mode, screening methods)
Thésaurus géographique
FRANCE
Thésaurus mots-clés
PREGABALINE
;
ETUDE DE CAS
;
MESUSAGE
;
PRISE EN CHARGE
;
ADDICTOVIGILANCE
;
SYNDROME DE SEVRAGE
;
EFFET SECONDAIRE
;
ETUDE RETROSPECTIVE
;
ANTICONVULSIVANTS
;
PHENOMENE EMERGENT
Résumé :
Pregabalin is indicated for the treatment of partial epilepsy, generalized anxiety disorder, and neuropathic pain. The first reports on pregabalin use disorder have been published in Europe in 2010 and notified to the French Addictovigilance Network (FAN) in 2011. The management of pregabalin use disorder is challenging due to the risks associated with the abrupt withdrawal and lack of guidelines. In this retrospective observational study, the management of pregabalin use disorder was analyzed in eight cases reported to the addictovigilance center of Montpellier, France, between 2019 and 2020. Most of these patients had a history of illicit psychoactive substance use. During the withdrawal period, patients experienced mainly psychiatric problems, nervous system symptoms, general disorders, and gastrointestinal symptoms. Multiple strategies were proposed for these patients to manage pregabalin withdrawal, such as hospitalization and pregabalin gradual dose reduction with or without adjuvant medications. Two patients relapsed and the others were lost to follow up. Although other reports of pregabalin use disorder have been published, recommendations or guidelines for its management are not yet available. The current case series and the previous reports suggest that the use of adjunctive therapy may be useful to limit the risk of convulsions and anxiety.
Affiliation :
Département de Pharmacologie Médicale et Toxicologie, Centre d'Addictovigilance, CHU Montpellier, Univ Montpellier, Montpellier, France
Département d'Addictologie, CHU Montpellier, Univ Montpellier, Montpellier, France
Département d'Addictologie, CHU Nîmes, France
Département d'Addictologie, CHU Montpellier, Univ Montpellier, Montpellier, France
Département d'Addictologie, CHU Nîmes, France